Neuren Pharmaceuticals Q3 2026 Sales Update
Key points
- Q3 2026 DAYBUE net sales up 39% from Q3 2025
- US$35 million milestone payment from DAYBUE launch in Germany
- Full year 2026 guidance upgraded to US$91 - 93 million
Full summary
Neuren Pharmaceuticals (ASX: NEU) reported strong Q3 2026 financial results, with DAYBUE net sales increasing by 39% compared to Q3 2025, reaching US$140 million. The company earned a US$35 million milestone payment following the launch of DAYBUE in Germany. Acadia Pharmaceuticals, Neuren's partner, also increased its full year 2026 global net sales guidance for DAYBUE to US$505 - 520 million. Neuren's total income from trofinetide is expected to be in the range of US$91 million to US$93 million for 2026.
Guidance
Full year 2026 guidance upgraded to US$91 - 93 million
Outlook
Neuren anticipates continued growth driven by strong DAYBUE uptake and potential new launches in Europe.
Summary generated by a large language model. Please interpret with care.